Overview

• Spain’s Testeavida PSA test, approved for EU use and distributed by Bidafarma, will provide preliminary PSA readings in 15 minutes at over 8,700 pharmacies
• Robotic prostatectomies at leading hospitals are cutting incontinence and erectile dysfunction rates below 10%, speeding patient recovery and preserving quality of life
• Stereotactic body radiotherapy (SBRT) is being scaled nationwide to deliver highly focused radiation in fewer sessions with minimal side effects for localized tumors
• Genetic profiling for BRCA1/2 and PSMA-targeted therapies—including PARP inhibitors and 177Lu-PSMA-617—are guiding tailored treatment plans and tripling survival for advanced cases
• Ongoing trials of immunotherapy and focal treatments like HIFU and cryoablation aim to expand less invasive options for early-stage and metastatic prostate cancer